Halozyme Therapeutics, Inc. vs. Scholar Rock Holding Corporation Common Stock
HALO
Halozyme Therapeutics, Inc.
$115.22 +2.47%
VS SRRKScholar Rock Holding Corporation Common Stock
$49.85 -2.62%
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| HALO | SRRK | |
|---|---|---|
| Market Cap | $12.76 billion | $6.07 billion |
| Revenue (TTM) | $1.66 billion | — |
| Net Income (TTM) | $413.60 million | $-408,591,000 |
HALO leads on 3 of 3 size & scale factors.
Valuation
| HALO | SRRK | |
|---|---|---|
| P/E Ratio | 33.59 | — |
| Price / Book | 88.91 | 23.92 |
| Price / Sales | 7.67 | — |
SRRK leads on 1 of 1 valuation factors.
Profitability
| HALO | SRRK | |
|---|---|---|
| Net Margin | 24.86% | — |
| Return on Equity | 288.13% | -161.00% |
HALO leads on 1 of 1 profitability factors.
Risk & Sentiment
| HALO | SRRK | |
|---|---|---|
| Short Interest | 9.79% | 0.11% |
SRRK leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, SRRK overview, SRRK financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.